Elevenostat for Your Research

September 2017  |  Press Releases

Elevenostat For Your Research-Exclusively From BioVision

FOR IMMEDIATE RELEASE

MILPITAS, Calif. - Aug. 31, 2017 - PRLog -- Elevenostat is a small molecule hydroxamic acid derivative, HDAC-11 inhibitor that has shown promising anti proliferative effect in in vitro and in vivo experiments.  Experimental data shows Elevenostat inhibits the growth of tumor and is effective against neuroblastoma, leukemia, prostate, lung and stomach cancer.

Reporter assays using a luciferase-linked Foxp3 promoter shows that HDAC11 decreases the signal driven by NFκB/p65, alone or in the presence of transfected Foxp3, and impairs luciferase activity driven by p65, Foxp3 and the HAT enzyme, p300. The inhibitory effects of HDAC11 at the Foxp3 promoter are reversed by Elevenostat (JB3-22), (IC₅₀ 0.235 µM). Elevenostat also partially reverses the inhibitory effect of HDAC11 on p300-induced Foxp3 acetylation at lysine 31 consistent with the ability of HDAC11 to directly regulate acetylation of Foxp3.

BioVision is exclusively offering Elevenostat, (HDAC11i, JB3-22) for your research use from milligram to Bulk quantities.

Please click here for more information: http://www.biovision.com/elevenostat.html

Contact us at [email protected]   and visit us at www.Biovision.com


About BioVision:

BioVision, Inc. is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, and more.